Pfizer: mixed study data for flu-Covid vaccine

(CercleFinance.com) - Pfizer and BioNTech announce initial mixed results for the Phase 3 clinical trial evaluating companies' combined mRNA vaccine candidate against influenza and Covid-19 in healthy people aged 18 to 64.


The trial failed to meet one of its primary immunogenicity objectives against influenza B, namely non-inferiority, despite achieving higher responses to influenza A and comparable responses to Covid-19 compared to comparator vaccines.

Both groups are currently evaluating adjustments to their vaccine candidate, aimed at improving immune responses against influenza B, and will discuss next steps with health authorities.

Pfizer also provides an update on its Phase 2 trial of trivalent mRNA influenza vaccine, which showed encouraging data with robust immunogenicity against all strains compared to a standard influenza vaccine.


Copyright (c) 2024 CercleFinance.com. All rights reserved.